TB-500 Peptide: Tissue Repair Research and FDA Status | telos rx
greyscale photo of woman in bralette inside room
← Back to blog
muscle recovery

TB-500 Peptide: Tissue Repair Research Overview

By TelosRX Editorial Team Updated

TB-500 is a short synthetic peptide based on part of thymosin beta-4, studied in preclinical research for tissue repair, inflammation and new blood vessel growth. It is not FDA-approved, and almost all of the evidence comes from animal and cell studies. Understanding the science, and the current regulatory status, helps you make informed decisions about the BPC-157 + TB-500 stack at telos rx.

What is TB-500 peptide?

TB-500 is a lab-made peptide modelled on the actin-binding region of thymosin beta-4 (Tβ4), a 43-amino-acid protein produced naturally in most human cells. It is usually described as an acetylated version of the short sequence LKKTETQ. In other words, TB-500 is a fragment or analog of Tβ4, not the full protein.

Tβ4 itself plays a role in cell migration, tissue repair and the regulation of inflammation across many tissue types. You will often read that TB-500 travels widely through muscles, joints, tendons and connective tissue rather than staying near the injection site. That idea comes mainly from animal work and online discussion, and it has not been established in humans.

The mechanism researchers focus on most is how Tβ4 handles actin, the structural protein cells use to move and change shape. Tβ4 binds and sequesters G-actin (single actin units), holding a ready pool that cells can draw on when they need to rebuild their internal scaffolding and migrate. It does not "upregulate" or increase actin production. Preclinical data suggest this role in cell movement is linked to wound closure, reduced inflammatory signalling and the formation of new blood vessels (angiogenesis) that supply healing tissue.

Because TB-500 is only a piece of Tβ4, results from studies on the full protein cannot be assumed to apply to TB-500 itself. For more on how the two differ, see our guide to thymosin beta-4 fragment research.

What the preclinical research shows

The bulk of the evidence comes from in vitro studies and animal models, and most of it was done on Tβ4 rather than TB-500. Human clinical data for TB-500 itself are essentially absent. That qualifier should frame how you read any specific benefit claim.

Published research on Tβ4 has examined several tissue types:

  • Wound healing: A 1999 study in rats (Malinda et al.) found that topical and systemic Tβ4 increased re-epithelialization, collagen deposition and new blood vessel growth in skin wounds compared with controls.
  • Muscle cells: Cell and animal studies have looked at whether Tβ4 influences muscle cell migration and regeneration after injury. Findings are early and have not been tested in human trials.
  • Tendon and ligament tissue: Tβ4-related peptides have been studied in animal tendon models as a possible aid to connective tissue repair. Human data are lacking.
  • Inflammatory signalling: Several animal and cell studies have examined Tβ4's ability to modulate inflammatory pathways, which is one reason it attracts interest in joint research.
  • Angiogenesis: Multiple studies have documented Tβ4's role in new blood vessel growth, which supports oxygen and nutrient delivery to healing tissue.
  • Hair follicles: Animal models have shown some activity in hair follicle growth, though this remains a separate and early line of research.

None of these studies are FDA-approved clinical evidence for human therapeutic use. The research provides a mechanistic rationale that has generated scientific interest, not an established treatment for any condition.

TB-500 vs BPC-157: key differences

TB-500 and BPC-157 are frequently compared in recovery research. Both show tissue repair activity in preclinical models, but they differ in origin, mechanism and evidence base.

Feature TB-500 BPC-157
Biological origin Synthetic fragment of thymosin beta-4 (a human protein) 15-amino-acid peptide derived from a protein in human gastric juice
Primary research focus Cell migration, wound repair, angiogenesis Tendon and ligament healing, gut lining, nitric oxide signalling
Distribution in body Often described as systemic; not established in humans Studied at and away from the administration site in animals
Administration studied Subcutaneous or intramuscular injection Subcutaneous injection; oral studied in animal models
FDA status Not FDA-approved; PCAC voted in July 2026 to recommend it for the compounding bulks list, pending FDA rulemaking; temporary HHS enforcement discretion policy since October 28, 2026 Not FDA-approved; same July 2026 PCAC recommendation and same temporary HHS policy, pending FDA rulemaking
Evidence stage Primarily animal and cell models, mostly on Tβ4 Animal models plus very limited human pilot data

Researchers have studied these peptides in combination, on the idea that their different mechanisms may complement each other. telos rx offers TB-500 only as part of the BPC-157 + TB-500 stack, not on its own. BPC-157 on its own is available as a BPC-157 injection, also subject to provider review. For a direct comparison in injury scenarios, see our guide to peptides studied for tendon repair.

Want a licensed provider to review whether the BPC-157 + TB-500 stack is appropriate for you?

See the BPC-157 + TB-500 stack

Dosing in the research literature

There are no published human clinical trials that establish a TB-500 dose, cycle length or schedule. The loading and maintenance figures that circulate online come from forums and anecdotal reports, not from controlled studies, so we do not reproduce them here. Nothing on this page is a dosing recommendation.

If a compounded peptide is appropriate for you, your provider sets the dose and schedule based on your health history and goals, and reviews it over time. Any therapeutic use is subject to medical approval by a licensed provider. Our article on how providers approach TB-500 dosing explains what goes into that decision.

Published research uses subcutaneous or intramuscular injection. No established bioavailability data support oral TB-500 in humans, so an oral product sold as TB-500 would not deliver the compound studied in preclinical models.

There is also no evidence-based timeline for results in humans. How a person responds depends on the condition, its severity, overall health and many other factors, and response is not guaranteed. Your provider decides how often to check in and whether to continue, adjust or stop.

Safety profile and known risks

Reported side effects in observational accounts are usually mild: temporary fatigue, headache, brief lightheadedness, nausea, flushing, and injection-site redness or tenderness. Long-term human safety has not been established.

The more significant concern is theoretical. Thymosin beta-4 is found at higher levels in several cancers, and because it is studied for cell migration and angiogenesis, researchers have raised the possibility that TB-500 could affect tumor growth or spread in people with active or undetected cancer. This has not been established in human studies, but people with cancer or a cancer history are commonly advised to avoid it, and a provider decides. It is not for use during pregnancy or breastfeeding.

TB-500 is not a steroid and has no androgenic effects. It is, however, on the WADA Prohibited List at all times, so tested athletes should not use it. What it lacks, compared with approved medications, is a long-term human safety record.

FDA regulatory status

TB-500 is not FDA-approved for any human therapeutic use.

In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157 and TB-500, among other peptides, to the list of bulk substances that can be used in compounding. The vote is advisory and non-binding. FDA must still complete rulemaking before the list changes, and its own briefing documents had recommended against. On October 28, 2026, HHS announced a temporary enforcement discretion policy that covers BPC-157 and TB-500, each as a single-ingredient compounded product under strict conditions, with TB-500 limited to subcutaneous or intramuscular use. It is not FDA approval, and HHS can revisit it. Our explainer on TB-500's regulatory status after the PCAC vote covers the details.

Grey-market vials labelled "research use only" are not made for human use, and their quality is unverified. They can be contaminated, mis-dosed or contain the wrong compound. A prescription filled by a licensed pharmacy is a different pathway.

At telos rx, we operate as an online, asynchronous telehealth service under LegitScript-certified standards. You complete an online intake, and a US-licensed provider reviews it without a scheduled appointment. If appropriate, the provider prescribes the BPC-157 + TB-500 stack, compounded by a licensed US pharmacy, subject to medical approval by a licensed provider. Approval is not guaranteed.

Frequently asked questions

What does TB-500 peptide do?

TB-500 is studied for tissue repair, inflammation and new blood vessel growth. Preclinical research, mostly on the parent protein thymosin beta-4, suggests a role in cell migration and wound healing. The evidence comes almost entirely from animal and cell studies, and human clinical trials of TB-500 itself are essentially absent.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a naturally produced 43-amino-acid protein. TB-500 is a short synthetic peptide based on its actin-binding region, usually described as acetylated LKKTETQ. The two are often discussed together, but TB-500 is a fragment, so results from studies on the full protein cannot be assumed to apply to it.

Is TB-500 FDA-approved?

No. TB-500 is not FDA-approved for any human use. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding it to the list of bulk substances that can be used in compounding. That vote is non-binding and is pending FDA rulemaking. Since October 28, 2026, a temporary HHS enforcement discretion policy covers single-ingredient compounded TB-500 under strict conditions; it is not FDA approval. telos rx prescribes the BPC-157 + TB-500 stack after provider review, compounded by a licensed US pharmacy.

Can TB-500 be taken orally?

No established bioavailability data support oral TB-500 in humans. Research uses subcutaneous or intramuscular injection. Oral products marketed as TB-500 are not delivering the same peptide studied in preclinical research.

How long does TB-500 take to work according to research?

There is no evidence-based timeline for TB-500 in humans, because controlled human trials have not been done. The week-by-week timelines found online are anecdotal. Response varies with the condition, its severity and overall health, and is not guaranteed. Your provider sets the review schedule.

What is the main safety risk of TB-500?

The most serious concern is theoretical: thymosin beta-4 is found at higher levels in several cancers, and it is studied for cell migration and angiogenesis, so people with cancer or a cancer history are commonly advised to avoid it. Common reported side effects, such as fatigue, headache and injection-site irritation, are generally mild. Long-term human safety is not established.

What peptides are studied as alternatives for tissue repair?

Several peptides with different research profiles are studied in tissue repair. BPC-157 has a large body of animal research on tendon and gut tissue. GHK-Cu is studied in skin and connective tissue. A provider evaluation identifies which options fit your situation.

Does TB-500 help with hair growth?

Animal research has shown thymosin beta-4 activity in hair follicle growth. Human clinical evidence for this use is lacking, and it is separate from the tissue repair research that generated most scientific interest in the compound.

Curious whether the BPC-157 + TB-500 stack is right for you? A licensed provider reviews your online intake. The stack is $133 per month if prescribed.

Explore the BPC-157 + TB-500 stack

telos rx is LegitScript-certified. BPC-157 and TB-500 are not FDA-approved, and compounded medications are not FDA-approved. Prescriptions are subject to medical approval by a licensed provider; approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.

Start your private evaluation on the BPC-157 + TB-500 page.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX